26 recruiting, 17 completed, 8 terminated, 7 active not recruiting. 22 Phase 1, 20 Phase 2, 8 Not applicable, 6 Phase 3, 1 Early Phase 1.
Follow Renal Cell Carcinoma (RCC): new trials by email Literature Review of Renal Cell Carcinoma (RCC) trials Research Report on Renal Cell Carcinoma (RCC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Characterizing the Genomic Landscape of Cancer in Native American Populations (NAT-Geno) Bio-specimen Collection, Blood Draw - Prostate Cancer, Renal Cell Carcinoma (RCC) | Recruiting | University of Oklahoma | 300 | 2026-11-02 | 2026-10-13 | |
| Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance Intermittent Fasting, Continuous Energy Restriction (CER) - Renal Cell Carcinoma (RCC) | Not applicable | Recruiting | Roswell Park Cancer Institute | 20 | 2026-11-01 | 2026-10-16 |
| Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 2 | Not yet recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-10-15 | 2026-10-13 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-08-18 |
| A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors VMD-102 - Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | VM Discovery, Inc. | 111 | 2026-07-16 | 2026-08-19 |
| First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain First-line systemic regimens - Renal Cell Carcinoma (RCC) | Active not recruiting | Bristol-Myers Squibb | 1200 | 2026-07-15 | 2026-10-01 | |
| 18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal Tumors 18F-N230A - Renal Cell Carcinoma (RCC), Renal Pelvic Urothelial Carcinoma | Not applicable | Recruiting | Peking University First Hospital | 80 | 2026-07-09 | 2026-10-15 |
| Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance Liver Cancer (Primary and Metastatic), Lung Cancer (Diagnosis) | Recruiting | Mark C Burgmans, MD PhD | 2000 | 2026-07-01 | 2026-09-01 | |
| To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer Anti-Human CD70 T-Cell Injection - Renal Cell Carcinoma (RCC) | Phase 1 | Recruiting | Hrain Biotechnology Co., Ltd. | 18 | 2026-06-30 | 2026-07-02 |
| Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy Anlotinib hydrochloride + Benmelstobart + Partial nephrectomy, Partial nephrectomy - Renal Cell Carcinoma (RCC) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 144 | 2026-05-31 | 2026-06-04 |
| A Phase 1 Study of the Safety and Tolerability of CTX-10726 CTX-10726 - Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC) | Phase 1 | Recruiting | Compass Therapeutics | 70 | 2026-05-28 | 2026-10-02 |
| Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy Ischemic preconditioning, NO ischemic preconditioning - Renal Cell Carcinoma (RCC), Renal Function Abnormal | Not applicable | Not yet recruiting | Sun Yat-sen University | 174 | 2026-04-01 | 2026-03-27 |
| CBCT Guided Markerless SBRT for Renal Cell Cancer Additional radiation due to imaging - Renal Cell Carcinoma (RCC) | Not applicable | Recruiting | Erasmus Medical Center | 40 | 2026-04-01 | 2026-04-08 |
| Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 3 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-03-25 | 2026-04-01 |
| Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis open or laparoscopic nephrectomy - Nonfunctioning Kidney, Renal Cell Carcinoma (RCC) | Not applicable | Recruiting | Menoufia University | 60 | 2026-02-01 | 2026-03-11 |
| Investigation of Lymph Node Biology in Kidney Cancer Peripheral Blood Sample for Immune Analysis, Tumor Sample for Analysis, Adjacent non-malignant kidney for analysis - Renal Cell Carcinoma (RCC) | Not applicable | Recruiting | Yale University | 33 | 2026-01-30 | 2026-06-16 |
| Cabozantinib Dose Skipping as an Alternative to Dose Reductions Cabozantinib - Renal Cell Carcinoma (RCC) | Phase 2 | Recruiting | dr. Tom van der Hulle | 34 | 2026-01-26 | 2026-08-31 |
| Sapu003 in Advanced mTOR-sensitive Solid Tumors Sapu003, Exemestane 25 MG - Breast Cancer Metastatic, Renal Cell Carcinoma (RCC) | Phase 1 | Recruiting | SAPU NANO (US) LLC | 27 | 2025-12-15 | 2026-01-27 |
| Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study Yivoximab - Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Enrolling by invitation | Sun Yat-sen University | 60 | 2025-11-01 | 2026-03-23 |
| A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI Vorolanib Tablets+Everolimus, Sunitinib - Renal Cell Carcinoma (RCC) | Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 116 | 2025-09-25 | 2025-09-10 |
Showing 20 of 66. Sign in to see all of them.
Carcinoma, Renal Cell (66) · Carcinoma, Hepatocellular (12) · Carcinoma, Non-Small-Cell Lung (12) · Kidney Neoplasms (9) · Colorectal Neoplasms (7) · Melanoma (7) · Ovarian Neoplasms (7) · Lung Neoplasms (5) · Neoplasm Metastasis (5) · Recurrence (5) · Stomach Neoplasms (5) · Carcinoma, Transitional Cell (4) · Squamous Cell Carcinoma of Head and Neck (4) · Triple Negative Breast Neoplasms (4) · Urinary Bladder Neoplasms (4)
Adenocarcinoma (66) · Carcinoma (66) · Female Urogenital Diseases (66) · Female Urogenital Diseases and Pregnancy Complications (66) · Male Urogenital Diseases (66) · Neoplasms by Histologic Type (66) · Neoplasms by Site (66) · Neoplasms, Glandular and Epithelial (66) · Urogenital Diseases (66) · Urogenital Neoplasms (66) · Urologic Diseases (66) · Urologic Neoplasms (66) · Kidney Diseases (65) · Neoplasms (64) · Kidney Neoplasms (57)
pembrolizumab (9) · Nivolumab (4) · toripalimab (4) · Ipilimumab (3) · Sunitinib (3) · cabozantinib (3) · pazopanib (3) · Injections (2) · Prednisone (2) · epacadostat (2) · spartalizumab (2) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · ARQ 197 (1) · Axitinib (1) · Bevacizumab (1)
Incyte Corporation (5) · Jinling Hospital, China (3) · Exelixis (2) · First Affiliated Hospital of Fujian Medical University (2) · GI Innovation, Inc. (2) · Ludwig Institute for Cancer Research (2) · Novartis Pharmaceuticals (2) · Sun Yat-sen University (2) · Telix Pharmaceuticals (Innovations) Pty Limited (2) · Tianjin Medical University Second Hospital (2) · University of Florida (2) · Advenchen Pharmaceuticals, LLC. (1) · Alliance for Clinical Trials in Oncology (1) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1) · Arcus Biosciences, Inc. (1)
United States (34) · China (21) · Australia (7) · Canada (7) · Spain (7) · Italy (5) · United Kingdom (5) · France (4) · Netherlands (4) · South Korea (4) · Germany (3) · Japan (3) · Austria (2) · Belgium (2) · Brazil (2)
Mark Jones, MD (2) · Adanma Ayanambakkam, MD, MS (1) · Alex Adjei, MD, PhD (1) · Andrew Gunn, MD (1) · Chaitanya R Divgi, MD (1) · Changyi Quan, MD (1) · Ciprian Catana, MD, Ph.D (1) · Cynthia Sirard, MD (1) · David Braun, MD (1) · Donglai Lv, MD (1) · Emil Kuriakose, MD (1)
PMID 22980441, PMID 26706103, PMID 17395103, PMID 22605650, PMID 28360208, PMID 32472319, PMID 33461782, PMID 37011650, PMID 38115208, PMID 38874883, PMID 39054430, PMID 39462179, PMID 39756444, PMID 39886141, PMID 41857358
2017 (2), 2023 (2), 2025 (2), 2018 (1), R01CA218187 (1)